Mylan Tenofovir Alafenamide Tablets Specifications
Brand Name : Hepbest
Form : Film Coated Tablets
Manufactured by : Mylan
Ingredients : Tenofovir Alafenamide
Strength : 25 mg
Packing : Pack of 30 Tablets
Package Type : Plastic Bottle
HepBest 25mg Tenofovir Alafenamide Tablet is the first drug in eight years that got approved for the management of chronic hepatitis B in India. HEPBEST -Tenofovir alafenamide fumarate tablet (TAF) is a nucleotide reverse transcriptase inhibitor. Moreover, it is a novel ester prodrug of the antiretroviral tenofovir that is to be used in the treatment of HIV infection and chronic hepatitis B. The treatment is applied in the form of tenofovir alafenamide fumarate (TAF). However, it is closely related to the commonly used reverse-transcriptase inhibitor TDF (tenofovir disoproxil fumarate).
Although, tenofovir disoproxil fumarate (TDF) has a good safety profile and efficacy, and it is also currently a cornerstone of HIV antiviral treatment. But its use has been associated with nephrotoxicity which causes reduced bone mineral density. In case of TAF it has been shown to have improved antiviral efficacy as well as enhanced delivery of TFV into peripheral blood mononuclear cells (PBMCs) and lymphatic tissues have a higher barrier to resistance and a much improved safety profile. Improved renal safety is likely attributable to lower circulating plasma concentrations of tenofovir and therefore less exposure and damage to bone and the kidneys, where tenofovir is metabolized.
According to World Health Organization there are more than 2 billion people worldwide who are infected with the HBV (hepatitis B virus) and among them more than 240 million people are infected with chronic liver infection.
Adults and adolescents (aged 12 years and older with body weight at least 35 kg): one tablet once daily.
In case of Treatment discontinuation:
Treatment discontinuation may be considered as follows:
• In HBeAgpositive patients without cirrhosis, treatment should be administered for at least 6-12 months after HBe seroconversion (HBeAg loss and HBV DNA loss with antiHBe detection) is confirmed or until HBs seroconversion or until there is loss of efficacy . Regular reassessment is recommended after treatment discontinuation to detect virological relapse.
• In HBeAgnegative patients without cirrhosis, treatment should be administered at least until HBs seroconversion or until there is evidence of loss of efficacy.
Missed dose: If a dose is missed and less than 18 hours have passed from the time it is usually taken, the patient should take Tenofovir Alafenamide tablets 25 mg as soon as possible and then resume their normal dosing schedule.